Combining enzyme and metabolic engineering for microbial supply of therapeutic phytochemicals

IF 7.1 2区工程技术 Q1 BIOCHEMICAL RESEARCH METHODS

Current opinion in biotechnology Pub Date : 2024-03-19 DOI:10.1016/j.copbio.2024.103110

Maxence Holtz, Carlos G Acevedo-Rocha, Michael K Jensen

{"title":"Combining enzyme and metabolic engineering for microbial supply of therapeutic phytochemicals","authors":"Maxence Holtz, Carlos G Acevedo-Rocha, Michael K Jensen","doi":"10.1016/j.copbio.2024.103110","DOIUrl":null,"url":null,"abstract":"<div><p>The history of pharmacology is deeply intertwined with plant-derived compounds, which continue to be crucial in drug development. However, their complex structures and limited availability in plants challenge drug discovery, optimization, development, and industrial production via chemical synthesis or natural extraction. This review delves into the integration of metabolic and enzyme engineering to leverage micro-organisms as platforms for the sustainable and reliable production of therapeutic phytochemicals. We argue that engineered microbes can serve a triple role in this paradigm: facilitating pathway discovery, acting as cell factories for scalable manufacturing, and functioning as platforms for chemical derivatization. Analyzing recent progress and outlining future directions, the review highlights microbial biotechnology’s transformative potential in expanding plant-derived human therapeutics’ discovery and supply chains.</p></div>","PeriodicalId":10833,"journal":{"name":"Current opinion in biotechnology","volume":"87 ","pages":"Article 103110"},"PeriodicalIF":7.1000,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0958166924000466/pdfft?md5=44b6b3a173f326e07e4d37b9cd6a9623&pid=1-s2.0-S0958166924000466-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in biotechnology","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0958166924000466","RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

The history of pharmacology is deeply intertwined with plant-derived compounds, which continue to be crucial in drug development. However, their complex structures and limited availability in plants challenge drug discovery, optimization, development, and industrial production via chemical synthesis or natural extraction. This review delves into the integration of metabolic and enzyme engineering to leverage micro-organisms as platforms for the sustainable and reliable production of therapeutic phytochemicals. We argue that engineered microbes can serve a triple role in this paradigm: facilitating pathway discovery, acting as cell factories for scalable manufacturing, and functioning as platforms for chemical derivatization. Analyzing recent progress and outlining future directions, the review highlights microbial biotechnology’s transformative potential in expanding plant-derived human therapeutics’ discovery and supply chains.

Abstract Image

查看原文本刊更多论文

结合酶工程和代谢工程，利用微生物提供治疗用植物化学物质

药理学的历史与植物提取的化合物深深地交织在一起，植物提取的化合物在药物开发中仍然至关重要。然而，这些化合物结构复杂，在植物中的可用性有限，这给药物发现、优化、开发以及通过化学合成或天然提取进行工业化生产带来了挑战。本综述深入探讨了如何整合代谢工程和酶工程，利用微生物作为可持续、可靠地生产治疗性植物化学物质的平台。我们认为，工程微生物可在这一模式中发挥三重作用：促进途径发现、充当可扩展生产的细胞工厂，以及作为化学衍生平台发挥作用。本综述分析了最近的进展并概述了未来的发展方向，强调了微生物生物技术在扩大植物源人类疗法的发现和供应链方面的变革潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current opinion in biotechnology 工程技术-生化研究方法

CiteScore

16.20

自引率

2.60%

发文量

226

审稿时长

4-8 weeks

期刊介绍： Current Opinion in Biotechnology (COBIOT) is renowned for publishing authoritative, comprehensive, and systematic reviews. By offering clear and readable syntheses of current advances in biotechnology, COBIOT assists specialists in staying updated on the latest developments in the field. Expert authors annotate the most noteworthy papers from the vast array of information available today, providing readers with valuable insights and saving them time. As part of the Current Opinion and Research (CO+RE) suite of journals, COBIOT is accompanied by the open-access primary research journal, Current Research in Biotechnology (CRBIOT). Leveraging the editorial excellence, high impact, and global reach of the Current Opinion legacy, CO+RE journals ensure they are widely read resources integral to scientists' workflows. COBIOT is organized into themed sections, each reviewed once a year. These themes cover various areas of biotechnology, including analytical biotechnology, plant biotechnology, food biotechnology, energy biotechnology, environmental biotechnology, systems biology, nanobiotechnology, tissue, cell, and pathway engineering, chemical biotechnology, and pharmaceutical biotechnology.